Procaps Group S.A. (NASDAQ:PROC) Sees Large Decline in Short Interest

Procaps Group S.A. (NASDAQ:PROC - Get Free Report) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 163,300 shares, a decrease of 21.7% from the November 30th total of 208,500 shares. Approximately 0.2% of the company's stock are sold short. Based on an average trading volume of 96,000 shares, the short-interest ratio is currently 1.7 days.

Procaps Group Stock Performance

Shares of NASDAQ PROC traded down $0.12 during mid-day trading on Friday, reaching $2.35. The company had a trading volume of 15,108 shares, compared to its average volume of 35,511. The company has a market capitalization of $265.13 million, a price-to-earnings ratio of 4.52 and a beta of 0.10. The stock has a fifty day moving average of $1.81 and a two-hundred day moving average of $2.06. Procaps Group has a 12-month low of $0.50 and a 12-month high of $4.95.

Procaps Group Company Profile

Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.